Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M663Revenue (TTM) $M32.0Net Margin (%)-503.7Altman Z-Score-7.4
Enterprise Value $M801EPS (TTM) $-1.5Operating Margin %-383.8Piotroski F-Score3
P/E(ttm)--Beneish M-Score-5.3Pre-tax Margin (%)-503.4Higher ROA y-yY
Price/Book--10-y EBITDA Growth Rate %--Quick Ratio5.6Cash flow > EarningsY
Price/Sales18.85-y EBITDA Growth Rate %29.3Current Ratio6.2Lower Leverage y-yN
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-79.8Higher Current Ratio y-yY
Dividend Yield %--PEG--ROE % (ttm)-383.8Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M108ROIC % (ttm)-449.7Gross Margin Increase y-yN

Gurus Latest Trades with KERX

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
(Average)*
Current Price Change from Average Comment Current Shares

KERX is held by these investors:



KERX: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Adams BrianGeneral Counsel and Secretary 2017-04-17Sell1,090$5.75-1.04view
Madison GregPresident and CEO 2017-04-05Sell911$5.8-1.9view
Adams BrianGeneral Counsel and Secretary 2017-04-05Sell642$5.8-1.9view
Madison GregPresident and CEO 2017-02-09Sell1,611$5.474.02view
Adams BrianGeneral Counsel and Secretary 2017-01-30Sell6,984$4.6522.37view
Neylan John F.Chief Medical Officer 2017-01-30Sell6,984$4.6522.37view
Holmes Scott ACFO 2017-01-30Sell8,447$4.6522.37view
Madison GregPresident and CEO 2017-01-30Sell18,248$4.6522.37view
Neylan John F.Chief Medical Officer 2017-01-23Sell1,428$5.395.57view
Adams BrianVP and General Counsel 2017-01-17Sell1,265$6.24-8.81view

Press Releases about KERX :

Quarterly/Annual Reports about KERX:

News about KERX:

Articles On GuruFocus.com
Keryx Biopharmaceuticals to Host Conference Call of First Quarter 2017 Financial Results on Thursday Apr 18 2017 
Keryx Announces the Largest Medicare Part D Plan Sponsor Added Auryxia® to its Medicare Part D Pl Mar 20 2017 
Keryx Biopharmaceuticals Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application f Mar 08 2017 
Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics as Price Declines Jul 12 2016 
Klarman Gives Insight on Keryx Biopharmaceuticals Investment Jan 26 2016 
Seth Klarman Blames Market, Investments for Rare Down Year Jan 25 2016 
David Abrams Buys Stake in Heavy Equipment Company Dec 15 2015 
Why Seth Klarman Keeps Buying Keryx Biopharma Nov 03 2015 
Seth Klarman Raises Position in Keryx Biopharmaceuticals Oct 21 2015 
Seth Klarman Buys Pharmaceutical Company's Shares to Fund Drug Launch Oct 12 2015 

More From Other Websites
Keryx Biopharmaceuticals to Host Conference Call of First Quarter 2017 Financial Results on... Apr 18 2017
Lawsuit for Investors in NASDAQ: KERX Shares Against Keryx Biopharmaceuticals Announced by... Apr 10 2017
ETFs with exposure to Keryx Biopharmaceuticals, Inc. : April 7, 2017 Apr 07 2017
Here's Why Keryx Biopharmaceuticals Jumped 27.3% in March Apr 07 2017
Why Is Keryx (KERX) Up 27.4% Since the Last Earnings Report? Apr 04 2017
Keryx's Auryxia Added to Largest Medicare Part D Plan Mar 22 2017
Omeros and Keryx are Potential Beneficiaries of New Administration Deregulation Mar 21 2017
Keryx Announces the Largest Medicare Part D Plan Sponsor Added Auryxia® to its Medicare Part D Plan... Mar 20 2017
Keryx Focuses on Kidney Drug Aurexia Despite Generic Threat Mar 16 2017
Blog Coverage Keryx Biopharma Announced FDA Review Approval for Auryxia(R) Tablets Mar 09 2017
3 Top Stocks Under $5 Mar 08 2017
Keryx Biopharmaceuticals Announces U.S. FDA Filing Acceptance of Supplemental New Drug Application... Mar 08 2017
Keryx Biopharmaceuticals, Inc. :KERX-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Mar 07 2017
SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Keryx Biopharmaceuticals, Inc. for... Mar 07 2017
Keryx (KERX) Q4 Loss Wider than Expected, Revenues Beat Mar 02 2017
Edited Transcript of KERX earnings conference call or presentation 1-Mar-17 1:00pm GMT Mar 01 2017
Keryx (KERX) Posts Wider-than-Expected Loss in Q4 Mar 01 2017
Keryx Biopharma reports 4Q loss Mar 01 2017
Keryx Biopharmaceuticals Announces Fourth Quarter and Full Year 2016 Financial Results Mar 01 2017
Should You Sell Keryx Biopharmaceuticals (KERX) Before Earnings? Feb 28 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)